[THE INVESTOR] On Oct. 20, Mezzion Pharma (140410) fell 5.93% to 21,400 won (US$19.07). It had declined 14.89% through the past month. Standard deviation, which indicates risk, records 2.7% on the same period over one month.

Compared with its close competitors within the same industry, KOSDAQ, the monthly volatility of Mezzion Pharma was not so high, the earnings rate for 1 month was also the lowest with decline of stock price. Over the recent month, the return-on-risk, the return on investment with consideration about risk, was -5.5%. As high volatility and a bearish stock price trend, the return-on-risk was poor, compared with its peer group. Moreover, compared with the KOSDAQ industry, the return-on-risk is below the industrial mean, -3.3, and thus the industrial comparison performance was not so good.

From Oct. 18, institutions have been continously buying Mezzion Pharma during the past 2 trading days. As a shareholding sum by investor group for the past 4 weeks, foreigners have sold 549 shares and institutions have sold 2,895 shares with dominant selling. However, during the same period, individuals have bought 3,444 shares lessening its position.

Cumulated shareholdings per investor group (1Mo) Total shareholdings per investor group

By HeRo (hero@heraldcorp.com)

This article is produced by the algorithm developed by the artificial intelligence developer ThinkPool in collaboration with Herald Corp.